Blade Therapeutics Reaches Enrollment Goal for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients With COVID-19 Pneumonia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Blade Therapeutics today announced that it has reached the 120-subject enrollment goal for the Phase 2 clinical study of the Company’s investigational therapeutic, BLD-2660, in the treatment of coronavirus disease-2019 (COVID-19) pneumonia. Also, an independent Data Monitoring Committee (DMC) recommended continuation of the trial without changes after conducting a planned review of blinded safety data. BLADE-CONQUER is a double-blind, placebo-contro

Click to view original post